Nurix Therapeutics to Discuss Latest Update on NX-5948 Clinical Trial at EHA 2024
Monday, 10 June 2024, 08:20
![https://store.livarava.com/57e3a323-271e-11ef-a412-9d5fa15a64d8.jpg](https://store.livarava.com/57e3a323-271e-11ef-a412-9d5fa15a64d8.jpg)
Nurix Therapeutics Webcast Update
Nurix Therapeutics is gearing up to host a webcast and conference call to delve into the latest developments surrounding the ongoing Phase 1 clinical trial of NX-5948. The event will highlight key data and insights presented at the prestigious European Hematology Association Congress (EHA) 2024.
Key Findings
- Significant Progress: The discussion will offer a detailed review of the progress made in the NX-5948 clinical trial.
- Insights and Implications: Attendees can expect to gain valuable insights into the implications of the trial results on the future of healthcare.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.